LOS ANGELES, Sept. 17, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mallinckrodt plc (“Mallinckrodt” or “the Company”) (NYSE: MNK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between February 28, 2018 and July 16, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before September 24, 2019.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at email@example.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Mallinckrodt’s H.P. Acthar Gel (“Acthar”) was a non-viable treatment for ALS based on serious safety concerns. Despite these safety issues, the Company touted Acthar as a viable ALS treatment. Based on these facts, the Company’s statements were false and materially misleading throughout the class period. When the market learned the truth about Mallinckrodt, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
The Schall Law Firm